Search results
Ocugen completes second cohort dosing in Stargardt trial By Investing.com
Investing.com· 12 hours agoOcugen, Inc. (NASDAQ: NASDAQ:OCGN), a biotechnology company, announced today the completion of...
A Dietitian Explains the Difference Between Chlorella and Spirulina—Do You Know Which Is Healthier?
Health.com· 14 hours agoSpirulina and chlorella are types of microalgae commonly taken in supplement form. They share some...
Regenerative medicine effort generates interest in Manchester growth
New Hampshire Union Leader, Manchester via Yahoo Finance· 5 days agoMay 10—One company in Manchester's Millyard is working on a retinal patch to help cure macular degeneration affecting people's vision. Another Millyard ...
Accelerating for universal eye health
World Health Organization· 3 days agoWomen, rural populations and ethnic minority groups are more likely to have vision impairment and least likely to access care. Impairment of vision...
Skye Bioscience (NASDAQ:SKYE) Shares Down 1.8%
ETF DAILY NEWS· 7 days agoSkye Bioscience, Inc. (NASDAQ:SKYE – Get Free Report)’s stock price was down 1.8% during trading on Wednesday . The company traded as low as $12.32 and last traded at $12.50. Approximately 29,170 ...
Johnson & Johnson (NYSE:JNJ) Shares Sold by Johnson Investment Counsel Inc.
ETF DAILY NEWS· 18 hours agoJohnson Investment Counsel Inc. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 12.4% in the 4th quarter, according to the company in its most recent disclosure with ...
Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 266.7% in April
ETF DAILY NEWS· 4 days agoAkari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 2,200 shares, a growth ...
Ranibizumab is Safe for Treating Retinopathy of Prematurity
UB Reporter· 3 days agoFor several decades, laser therapy has been the primary treatment method for ROP. Laser treatment involves burning the infant’s peripheral retina to stop the proliferation of the abnormal blood ...
Earnings call: Ocugen reports progress in gene therapy trials and Q1 financials By Investing.com
Investing.com· 1 day agoOcugen, Inc. (NASDAQ: NASDAQ:OCGN) discussed significant advancements in its gene therapy programs...
Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...
GuruFocus.com via Yahoo Finance· 21 hours agoOcugen Inc (NASDAQ:OCGN) has successfully completed dosing in Phase 1/2 trials for OCU410 and OCU410ST, targeting dry age-related macular degeneration and ...
